Literature DB >> 27183307

Tailoring risk communication to improve comprehension: Do patient preferences help or hurt?

Andrew J Barnes1, Yaniv Hanoch2, Talya Miron-Shatz3, Elissa M Ozanne4.   

Abstract

OBJECTIVE: Risk communication tools can facilitate patients' understanding of risk information. In this novel study, we examine the hypothesis that risk communication methods tailored to individuals' preferences can increase risk comprehension.
METHOD: Preferences for breast cancer risk formats, and risk comprehension data were collected using an online survey from 361 women at high risk for breast cancer. Women's initial preferences were assessed by asking them which of the following risk formats would be the clearest: (a) percentage, (b) frequency, (c) bar graph, (d) pictogram, and (e) comparison to other women. Next, women were presented with 5 different formats for displaying cancer risks and asked to interpret the risk information presented. Finally, they were asked again which risk format they preferred.
RESULTS: Initial preferences for risk formats were not associated with risk comprehension scores. However, women with lower risk comprehension scores were more likely to update their risk format preferences after they evaluated risks in different formats. Less numerate women were more likely to prefer graphical rather than numeric risk formats. Importantly, we found that women preferring graphical risk formats had lower risk comprehension in these formats compared to numeric formats. In contrast, women preferring numeric formats performed equally well across formats.
CONCLUSIONS: Our findings suggest that tailoring risk communication to patient preferences may not improve understanding of medical risks, particularly for less numerate women, and point to the potential perils of tailoring risk communication formats to patient preferences. (PsycINFO Database Record (c) 2016 APA, all rights reserved).

Entities:  

Mesh:

Year:  2016        PMID: 27183307     DOI: 10.1037/hea0000367

Source DB:  PubMed          Journal:  Health Psychol        ISSN: 0278-6133            Impact factor:   4.267


  6 in total

1.  Serious and actionable risks, plus disclosure: Investigating an alternative approach for presenting risk information in prescription drug television advertisements.

Authors:  Kevin R Betts; Vanessa Boudewyns; Kathryn J Aikin; Claudia Squire; Suzanne Dolina; Jennifer J Hayes; Brian G Southwell
Journal:  Res Social Adm Pharm       Date:  2017-08-02

2.  Do Preferred Risk Formats Lead to Better Understanding? A Multicenter Controlled Trial on Communicating Familial Breast Cancer Risks Using Different Risk Formats.

Authors:  Lidewij Henneman; Christi J van Asperen; Jan C Oosterwijk; Fred H Menko; Liesbeth Claassen; Daniëlle Rm Timmermans
Journal:  Patient Prefer Adherence       Date:  2020-02-19       Impact factor: 2.711

Review 3.  Covering patient's perspective in case-based critical review articles to improve shared decision making in complex cases.

Authors:  Louis-Rachid Salmi; Pierre Côté; Christine Cedraschi
Journal:  Health Expect       Date:  2020-07-23       Impact factor: 3.377

Review 4.  Effective communication regarding risk of fracture for individuals at risk of fragility fracture: a scoping review.

Authors:  Charlotte Beaudart; Mickael Hiligsmann; Nannan Li; E Michael Lewiecki; Stuart Silverman
Journal:  Osteoporos Int       Date:  2021-09-24       Impact factor: 4.507

5.  How People Understand Risk Matrices, and How Matrix Design Can Improve their Use: Findings from Randomized Controlled Studies.

Authors:  Holly Sutherland; Gabriel Recchia; Sarah Dryhurst; Alexandra L J Freeman
Journal:  Risk Anal       Date:  2021-09-14       Impact factor: 4.302

6.  The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence.

Authors:  Nancy K Janz; Yun Li; Brian J Zikmund-Fisher; Reshma Jagsi; Allison W Kurian; Lawrence C An; M Chandler McLeod; Kamaria L Lee; Steven J Katz; Sarah T Hawley
Journal:  Breast Cancer Res Treat       Date:  2016-12-09       Impact factor: 4.624

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.